Posts Tagged ‘semaglutide’

Another Piece of the Heart Failure Puzzle for Semaglutide

August 24, 2024 — Novo Nordisk is creeping up on an indication for semaglutide in people with obesity and heart failure. Today in Lancet, we have another piece of the puzzle to suggest this drug might help. In a prespecified analysis from the SELECT study, researchers found that semaglutide reduced heart attacks, strokes, deaths, and problems with heart failure […]

Let’s Reflect Upon 94% Prevention of Diabetes with Tirzepatide

August 21, 2024 — Yesterday, Eli Lilly and Company announced an impressive topline number from the results of a three-year study of tirzepatide in adults with obesity or overweight and prediabetes. That number was 94% prevention of progression from prediabetes to diabetes with tirzepatide. No, it was not 100%. But this is awfully close. Historical Context We will have to […]

The Next Revolution in Obesity Medicines

August 20, 2024 — Semaglutide – under the banner of Ozempic – has set a revolution of obesity medicines in motion. Suddenly, all of the huffing and puffing about “treating obesity seriously” and “obesity as a disease” is moot. Facts on the ground are persuading people to re-orient their thinking about obesity faster than essays and advocacy campaigns ever […]

From No to Maybe on Compounded Obesity Medicines

August 17, 2024 — Never is a long time and repeatedly telling people NO can be a futile exercise. Thus, doctors are landing somewhere between no and maybe on the use of compounded obesity medicines. Some are seeing a rationale for for using them while others remain resolute in opposition to them. Shauna Levy is an obesity medicine physician […]

Lilly and Novo Nordisk: The Best of Times, the Worst of Times

August 9, 2024 — This week has given us a study in contrasts. The leading makers of obesity medicines, Lilly and Novo Nordisk, posted quarterly reports and received sharply different responses. When Novo Nordisk released their report on Wednesday, the market value of the stock plunged by eight percent. The next day, Lilly reported results and saw its market […]

When Will the Short Supply of GLP1s Be Behind Us?

August 5, 2024 — Should we celebrate the news that, in FDA drug shortage listings, all forms of tirzepatide (Mounjaro and Zepbound) are listed as “available”? Is this a sign that we are on our way to the nightmarishly short supply of GLP1s will soon be behind us? Forgive us for being skeptical, but we’re not quite ready to […]

A GLP-1, Liraglutide, Shows Potential to Slow Down Alzheimer’s

August 1, 2024 — On the theme of “Is there anything GLP-1s can’t do?” a new randomized controlled trial is coming at us from the Alzheimer’s Association International Conference. It showed promising signs that a GLP-1, liraglutide, might slow the progression of Alzheimer’s disease. Liraglutide is used under the brand name Victoza to treat type 2 diabetes. At higher […]

Do People with Diabetes Smoke Less on Semaglutide?

July 31, 2024 — A fascinating new study in Annals of Internal Medicine asks an important question. When people receive semaglutide for type 2 diabetes, are they less likely to smoke? This is not such a random question. In fact, clinicians are reporting striking reductions in addictive behaviors by people receiving it for obesity. So William Wang and colleagues […]

The Unfortunate Gray Market for Obesity Medicines

July 22, 2024 — A gray market for obesity medicines is thriving. The quality of the products in this market range from reasonable to sketchy to utterly unreliable. But millions of people are taking a chance on them. Big pharma companies innovated to bring fully vetted formulations of important medicines to market, spending billions of dollars to do it. […]

Another Suggestion Semaglutide Might Cut Dementia Risk

July 15, 2024 — What should we take away from yet another suggestion that semaglutide might cut the risk of dementia? An Unexpected Finding This latest hint was a surprise. It comes from research that aimed to measure the risk of neurological and psychiatric problems associated with taking semaglutide for type 2 diabetes. Riccardo De Giorgi and colleagues were […]